Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) Stock Price & Analysis

2 Followers

8189 Stock Chart & Stats

HK$0.13HK$0.01(5.69%)
At close: 4:00 PM GMT+8
HK$0.15HK$0.2HK$0.25Aug 10Aug 24Sep 7Sep 21Oct 7Oct 20Nov 2
Day’s Range
HKD 0.12 - HKD 0.13
52-Week Range
HKD 0.11 - HKD 0.40
Previous Close
HKD 0.12
Volume
N/A
Average Volume (3M)
384.17K
Market Cap
HKD 277.41M
Enterprise Value
HKD 350.33M
Total Cash (Recent Filing)
HKD 65.29M
Total Debt (Recent Filing)
HKD 108.79M
Price to Earnings (P/E)
―
Beta
0.26
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

2025 Revenue Rebound

The sharp 2025 revenue rebound indicates that the company regained substantial top-line activity after a weaker period. Although profitability has not yet followed, renewed sales scale can provide a broader base for operating leverage and future margin recovery if the improvement persists.

Reported Revenue Growth

Positive reported revenue growth supports the view that the business is still generating meaningful commercial activity rather than experiencing a sustained contraction. Continued expansion would improve the company’s ability to spread fixed costs and strengthen its platform for eventual earnings improvement.

Healthcare Product Focus

Exposure to pharmaceutical and medical-related products gives the company a clear healthcare operating focus and a business model tied to essential product categories. This focus provides ongoing relevance in healthcare markets and a foundation for growth if execution and product sales improve.

Bears Say

Extreme And Rising Leverage

Rapidly rising leverage and a debt-to-equity ratio near 9.0x materially reduce financial flexibility. With equity sharply lower, the company has less capacity to absorb continued losses, fund expansion internally, or withstand pressure without greater dependence on external financing.

Persistent Negative Cash Flow

Four consecutive years of negative operating cash flow, worsening in 2025, show that reported operations are not converting into cash. Persistently negative free cash flow increases reliance on outside funding and can constrain investment, debt servicing, and the company’s ability to sustain operations.

Weak And Deteriorating Profitability

Low gross profitability combined with continuing operating losses and a materially wider net loss indicates that the revenue rebound has not translated into a sustainable earnings model. Without margin improvement, higher sales may continue to add limited financial value while losses erode equity.

8189 FAQ

What was Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price range in the past 12 months?
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H lowest stock price was HK$0.11 and its highest was HK$0.40 in the past 12 months.
What is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s market cap?
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s market cap is HK$277.41M.
When is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s earnings last quarter?
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H released its earnings results on Aug 31, 2026. The company reported HK$0.005 earnings per share for the quarter.
Is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Tianjin TEDA Biomedical Engineering Co. Ltd. Class H pay dividends?
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H does not currently pay dividends.
What is Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s EPS estimate?
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianjin TEDA Biomedical Engineering Co. Ltd. Class H have?
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has 1,436,400,000 shares outstanding.
What happened to Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s price movement after its last earnings report?
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H reported an EPS of HK$0.005 in its last earnings report. Following the earnings report the stock price went down -1.961%.
Which hedge fund is a major shareholder of Tianjin TEDA Biomedical Engineering Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:8189
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology